QURE AMT-130 BLA: First Huntington's Gene Therapy Filing

uniQure (QURE) filed a Biologics License Application with the FDA on September 2 seeking accelerated approval of AMT-130, its one-time gene therapy for Huntington’s disease. It also submitted a marketing application to the UK’s MHRA the same day. Shares closed at $46.23, down 4.7% on the news, leaving a roughly $3.3 billion market cap.

AMT-130, formally ifezuntirgene inilparvovec, is an AAV5 vector that delivers a microRNA to silence the huntingtin gene at the source. It is the first Huntington’s drug to hold FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Fast Track designations. uniQure requested priority review, which would compress the review to roughly six months after a 60-day filing-acceptance period.

The application rests on three-year Phase I/II data compared against a propensity-score-matched external control from the Enroll-HD natural history registry, not a randomized trial. At 36 months, high-dose patients showed a 75% slowing of disease progression on the cUHDRS scale (p=0.003). The FDA pushed back hard in November 2025, then reversed course after a June 2026 Type B meeting and agreed the data could support an accelerated approval filing. A prior deep dive on the AMT-130 Huntington’s gene therapy filing covers the science and valuation in full, and the accelerated approval pathway explains what a confirmatory study means here.

Huntington’s is an invariably fatal inherited disorder with no approved disease-modifying therapy. Roche’s RG6042, PTC Therapeutics’ PTC518, and Alnylam’s ALN-HTT02 are all earlier in development, so uniQure holds a multi-year lead.

About 75,000 people have manifest Huntington’s in the US, EU, and UK, with hundreds of thousands more at genetic risk, and the disease progresses relentlessly from motor and cognitive decline to death. AMT-130 is not a pill or an injection: it is delivered by MRI-guided, convection-enhanced neurosurgery directly into the striatum. That surgical complexity, plus AAV5 manufacturing at commercial scale, means a launch would roll out slowly through a limited number of specialized centers.

The catch is the evidence bar. The FDA has not yet accepted the filing, and the confirmatory study design, likely a concurrent standard-of-care control rather than sham surgery, is still being negotiated. Accelerated approval would require uniQure to confirm clinical benefit after launch, and a 12-patient efficacy dataset stacked against an external control remains the core regulatory risk.

Watch for three events: BLA acceptance within about 60 days, the priority review decision, and a four-year data readout promised before the end of the third quarter. If the agency accepts the external-control design, it validates a faster path other rare-disease gene-therapy programs are watching closely.

Source: uniQure AMT-130 BLA submission press release